The immunophenoscore (IPS) further validated the fact that high LDHD tumor was associated with high immunogenicity and that the high LDHD group might benefit from the CTAL4 + /PD1- therapy (Fig. 9E-H). This evidence concerns the gene PDCD1 and neoplasm.